SPR Therapeutics

SPR Therapeutics is a private medical device company headquartered in Cleveland, Ohio, with additional offices in Chapel Hill, North Carolina, and Minneapolis, Minnesota. The company specializes in a minimally invasive, non-opioid pain treatment option through its SPRINT Peripheral Nerve Stimulation (PNS) System.

The SPRINT PNS System is a 60-day treatment aimed at reconditioning the central nervous system to provide significant and sustained relief from chronic pain without a permanent implant, nerve destruction, or the risk of addiction. The system utilizes flexible, robust, minimally-invasive leads to deliver temporary peripheral nerve stimulation (PNS). The most recent innovation, MicroLead 2.0, enhances the performance of the SPRINT PNS System with increased strength, greater durability, and improved clinical performance.

The SPRINT PNS System has been extensively studied for various pain conditions, including low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain. As of March 2023, the company announced reaching the milestone of its 20,000th patient implant of the SPRINT PNS System. In February 2024, SPR Therapeutics secured USD 85 million in financing to capitalize on commercial momentum and expand its sales representation across the US.

In 2023, the company obtained expanded FDA clearance, increasing the intended patient population for the SPRINT PNS System and introducing new advancements to enhance and simplify the lead securement mechanism. Additionally, SPR Therapeutics announced the introduction of the SPRINT extensa XT System with bimodal PNS, designed to deliver a comprehensive approach to pain alleviation by treating dual nerve targets with synergistic stimulation modalities.